The Royal Marsden NHS Foundation Trust shared on LinkedIn:
“NEWS: People with localised prostate cancer could benefit from advanced radiotherapy as an alternative to surgery while maintaining long-term cancer control.
Eight-year follow-up data from the PACE-A study suggests that five sessions of Stereotactic Body Radiation Therapy (SBRT) may be just as effective as radical prostatectomy for long-term disease control.
Findings from the PACE-A clinical trial, a multi-centre Phase 3 randomised controlled trial led by The Royal Marsden NHS and The Institute of Cancer Research, have been presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.
Treatment decisions about localised prostate cancer are often informed by concerns about the potential long-term impact on the patient’s urinary, bowel, and sexual function. These results may help patients and clinicians make more informed decisions regarding quality of life when choosing treatment.
“It is essential that patients with prostate cancer are aware of all the options available to them,” says Professor Nicholas van As, Chief Investigator of the PACE-A trial.
“Treatment choices are often driven by the desire to preserve long-term urinary and sexual function, but until now we have had limited randomised evidence comparing the long-term cancer outcomes of surgery and SBRT. The PACE-A trial was designed to address this gap.
“Now, these results show that SBRT appears to achieve comparable long-term cancer control to surgery, helping patients make more informed decisions about their care.”
Read the full story: People with localised prostate cancer could benefit from advanced radiotherapy as an alternative to surgery while maintaining long-term cancer control.”
Other articles about Prostate Cancer and radiotherapy on OncoDaily.